<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607748</url>
  </required_header>
  <id_info>
    <org_study_id>39453</org_study_id>
    <nct_id>NCT02607748</nct_id>
  </id_info>
  <brief_title>18F-fluoride (18F-NaF) PET for Identifying Coronary Atherosclerotic Plaques</brief_title>
  <official_title>18F-fluoride (18F-NaF) Positron Emission Tomography (PET) for Identification of Ruptured and High-Risk Coronary Atherosclerotic Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether 18F-NaF (sodium fluoride) Positron Emission
      Tomography (PET) scans can be used to identify ruptured and high-risk plaque as compared to
      non-invasive coronary Computed Tomography Angiography (CTA) scans and high-definition
      intravascular ultrasound (IVUS).

      In subsets of patients, 18F-NaF PET scans and CCTA will be repeated to assess scan-rescan
      reproducibility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research involves having cardiac 18F-NaF PET imaging of the heart and coronary Computed
      Tomographic Angiography (CTA) in a one-day visit. Three groups of patients will be enrolled:
      patients with Acute Coronary Syndrome, patients with stable ischemic heart disease, and
      asymptomatic patients with suspected coronary artery disease.

      Prior to 18F-NaF administration, participants will have blood drawn to measure serum
      creatinine and other biomarkers related to heart disease.

      All participants will undergo a 18F-NaF PET scan and a coronary CTA (which includes contrast
      administration). If medically appropriate, participants will have oral or intravenous
      beta-blocker (metoprolol) and nitroglycerin prior to CTA imaging.

      Up to 10 patients will be asked to return for repeat18F-NaF PET and coronary CTA imaging 2 to
      21 days after the initial scan. Up to 20 patients will be asked to return for repeat 18F-NaF
      PET scan and coronary CTA imaging about 6 months after the initial scan. Researchers will
      compare the repeat images to the initial studies.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target-to-background ratio (TBR) uptake of 18F-NaF</measure>
    <time_frame>one day</time_frame>
    <description>a comparison of the uptake of 18F-NaF in an atherosclerotic plaque lesion compared to the background (superior vena cava)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerotic Plaque</condition>
  <arm_group>
    <arm_group_label>18F-NaF PET and coronary CTA imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-NaF PET and coronary CTA imaging</intervention_name>
    <arm_group_label>18F-NaF PET and coronary CTA imaging</arm_group_label>
    <other_name>18F-NaF (sodium fluoride) PET</other_name>
    <other_name>sodium fluoride PET</other_name>
    <other_name>coronary CTA</other_name>
    <other_name>CCTA</other_name>
    <other_name>coronary CT Angiography</other_name>
    <other_name>non-invasive coronary CT Angiography</other_name>
    <other_name>non-invasive coronary plaque imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Three groups of patients will be recruited for this study.

          1. Acute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21
             days prior to the imaging visit and invasive coronary angiography with angiographic
             evidence of at least a 50% stenosis in one or more coronary arteries. Only patients
             undergoing PCI will be included in the study.

          2. Stable Ischemic Heart Disease group: 40 patients who have undergone invasive coronary
             angiography within 21 days prior to the imaging visit, with history of typical angina
             prior to the angiogram, but no prior myocardial infarction or coronary
             revascularization.

          3. Asymptomatic CAD group: 40 patients who have undergone Coronary Artery Calcium
             scanning within 6 months prior to the imaging visit, matched to the ACS patients for
             age, gender, and CAC score.

               -  Patients in the asymptomatic CAD group must

                    -  have no prior CAD associated event (no prior myocardial infarction, acute
                       coronary syndrome, coronary angiogram, or PCI),

                    -  have CAC between 10 to &lt;1000, and

                    -  match to patients in the ACS group by gender, age by decile, and CAC
                       category (using CAC categories of 10 to &lt;100, 100 to &lt;400, 400 to &lt;1000).

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Creatinine &gt; 1.5 mg/dL

          -  History of severe allergy to Iodine contrast agents

          -  Pregnancy

          -  Active atrial fibrillation

          -  Multiple premature ventricular or atrial contractions

          -  Ejection fraction &lt;35%

          -  Class III congestive heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S. Berman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel s. Berman</last_name>
    <phone>310 423-4223</phone>
    <email>bermand@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rhona Littman</last_name>
    <phone>310 423-4387</phone>
    <email>littmanr@cshs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel S Berman, MD</last_name>
      <phone>310-423-4223</phone>
      <email>bermand@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Daniel S Berman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel S. Berman</investigator_full_name>
    <investigator_title>Chief, Nuclear Cardiology and Cardiac Imaging</investigator_title>
  </responsible_party>
  <keyword>18F-NaF PET</keyword>
  <keyword>18F-sodium fluoride PET</keyword>
  <keyword>Coronary CTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
    <mesh_term>Listerine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

